What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives

K Peng, BB Liang, W Liu, ZW Mao - Coordination Chemistry Reviews, 2021 - Elsevier
Encouraged by the worldwide success of cisplatin in the field of cancer chemotherapy,
intensive works have been conducted to explore more platinum coordination complexes as …

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

X Meng, QY Lou, WY Yang, YR Wang… - Cancer …, 2021 - Wiley Online Library
Oral squamous cell carcinoma (OSCC), the eighth most prevalent cancer in the world, arises
from the interaction of multiple factors including tobacco, alcohol consumption, and betel …

Multi-action Pt (IV) anticancer agents; do we understand how they work?

D Gibson - Journal of inorganic biochemistry, 2019 - Elsevier
Pt (IV) complexes act as prodrugs that are activated inside cancer cells releasing cytotoxic Pt
(II) drugs such as cisplatin as well as two axial ligands. These ligands can be used to confer …

Platinum (IV) antitumor complexes and their nano-drug delivery

C Jia, GB Deacon, Y Zhang, C Gao - Coordination Chemistry Reviews, 2021 - Elsevier
Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but
problems such as systemic toxicity and acquired resistance for some primary tumors hamper …

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways

G Leon, L MacDonagh, SP Finn, S Cuffe… - Pharmacology & …, 2016 - Elsevier
Lung cancer is the leading cause of cancer mortality worldwide. Despite advances in anti-
cancer therapies such as chemotherapy, radiotherapy and targeted therapies, five-year …

YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation

CS Huang, YQ Zhu, QC Xu, S Chen… - Clinical and …, 2022 - Wiley Online Library
Background Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with
exceedingly poor prognosis, and chemoresistance is a huge challenge for treatment. N6 …

Developing a copper (II) agent based on his-146 and his-242 residues of Human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit …

M Jiang, Z Zhang, W Li, X Man, H Sun… - Journal of Medicinal …, 2022 - ACS Publications
To overcome the resistance of nonsmall cell lung cancer (NSCLC) cells to cisplatin and
inhibit their metastasis, we proposed to develop a Cu (II) agent based on the specific residue …

Advances in Stigmasterol on its anti-tumor effect and mechanism of action

X Zhang, J Wang, L Zhu, X Wang, F Meng, L Xia… - Frontiers in …, 2022 - frontiersin.org
Stigmasterol is a phytosterol derived from multiple herbaceous plants such as herbs,
soybean and tobacco, and it has received much attention for its various pharmacological …

[HTML][HTML] Basic research on curcumin in cervical cancer: Progress and perspectives

X Zhang, L Zhu, X Wang, H Zhang, L Wang… - Biomedicine & …, 2023 - Elsevier
Curcumin is a polyphenolic substance extracted from plants such as Curcuma longa,
Curcuma zedoaria, and radix curcumae, and it has attracted much attention because of the …

Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles

AV Nascimento, A Singh, H Bousbaa, D Ferreira… - Acta biomaterialia, 2017 - Elsevier
Efficiency of chemotherapy is often limited by low therapeutic index of the drug as well as
emergence of inherent and acquired drug resistance in cancer cells. As a common strategy …